Trulicity Cost in Louisiana 2026: Cash Price, Medicaid, and Compounded Dulaglutide Options

What Does Trulicity Actually Cost in Louisiana in 2026?

The cash price for Trulicity in Louisiana sits at $931 per month regardless of which of the four available doses a patient uses: 0.75 mg, 1.5 mg, 3 mg, or 4.5 mg. That price reflects Eli Lilly's manufacturer list price and is consistent across major retail chains including CVS, Walgreens, and Walmart pharmacies statewide. Patients paying without insurance or a savings program face the full $931 for a four-pen carton (a 28-day supply at once-weekly dosing).

GLP-1 receptor agonists like dulaglutide are among the most expensive medication classes in U.S. outpatient care. A 2023 analysis published in JAMA found that the average net price paid for GLP-1 drugs after rebates was still well above $500 per month for most commercially insured patients, making out-of-pocket cost a genuine barrier to adherence. [1]

The price has not changed meaningfully between 2025 and 2026 for Louisiana residents. No state-level pricing legislation specific to GLP-1 drugs has passed in Louisiana as of this writing. Patients who rely on cash pay should contact individual pharmacies for GoodRx or manufacturer coupon layering options, though stacking those discounts with insurance is not permitted under most plan rules.

Does Louisiana Medicaid Cover Trulicity?

Louisiana Medicaid does not cover Trulicity (dulaglutide) as of 2026. The Louisiana Department of Health's Medicaid Preferred Drug List places dulaglutide in a non-covered tier for the state's managed-care Medicaid program, Healthy Louisiana. This means prior authorization requests are unlikely to succeed for most Medicaid enrollees regardless of the clinical rationale.

Louisiana Medicaid does cover certain other diabetes medications. Metformin, sulfonylureas, and some insulins remain on the preferred list without restriction. Some GLP-1 agents with different chemical structures have achieved coverage in other state Medicaid programs, but dulaglutide specifically has not crossed that threshold in Louisiana. [2]

Patients on Medicaid who need a GLP-1 receptor agonist should discuss with their prescriber whether semaglutide (Ozempic) or liraglutide (Victoza) has better Medicaid coverage in Louisiana, though coverage for the entire class remains limited statewide.

The 2023 American Diabetes Association Standards of Care recommend GLP-1 receptor agonists as a preferred add-on therapy when A1C control is inadequate on metformin alone, particularly in patients with established cardiovascular disease. [3] Louisiana's Medicaid formulary gaps create a direct conflict with those clinical guidelines for low-income diabetic patients.

Which Commercial Insurance Plans Cover Trulicity in Louisiana?

Most major commercial insurance plans operating in Louisiana do cover Trulicity, though typically with prior authorization and step-therapy requirements. Blue Cross and Blue Shield of Louisiana, Humana, Aetna, and UnitedHealthcare all list dulaglutide on their formularies as of early 2026, usually in Tier 3 or Tier 4. Tier placement matters: a Tier 4 specialty copay on a Blue Cross of Louisiana plan could run $80 to $150 per fill even after negotiated discounts.

Step therapy is common. Many Louisiana commercial plans require documented failure on at least one less expensive agent, often metformin plus a sulfonylurea, before approving a GLP-1. Your prescriber must submit a prior authorization form with supporting A1C values and medication history. Approval timelines typically run 3 to 10 business days.

The FDA approved dulaglutide's cardiovascular indication in 2020 based on the REWIND trial (N=9,901), which showed a statistically significant 12% relative risk reduction in major adverse cardiovascular events (MACE) versus placebo over a median 5.4-year follow-up period. [4] That cardiovascular label can strengthen prior authorization arguments for patients with documented atherosclerotic cardiovascular disease, because denying a drug with an active CV-risk indication carries greater medical and legal weight for insurers.

Employer-sponsored plans in Louisiana that are self-funded and governed by ERISA may have different formularies than state-regulated individual or small-group plans. Employees should call the member services number on their insurance card and ask specifically about dulaglutide prior authorization criteria rather than assuming Trulicity coverage mirrors coverage for other diabetes drugs.

How the Eli Lilly Savings Card Works in Louisiana

Eli Lilly offers the Trulicity Savings Card through its website and via participating pharmacies. Commercially insured patients who qualify may pay as little as $25 per monthly fill, with Lilly covering the remaining balance up to a defined program cap. As of 2026, Lilly has maintained this program for eligible patients with private insurance who meet income and enrollment criteria.

The card does not work for patients covered by Medicare, Medicaid, CHIP, or any other federal or state government payer. Louisiana Medicaid patients are categorically excluded. Medicare Part D patients are also excluded under federal anti-kickback safe harbor rules.

Enrollment takes about five minutes on Lilly's patient support site. Once enrolled, the card functions like a secondary insurance benefit at the pharmacy counter. The pharmacist runs your insurance first, then applies the Lilly savings card to the remaining patient cost-share. Patients do not need to submit paperwork retroactively.

Lilly also runs the Lilly Cares Foundation patient assistance program, which provides Trulicity at no cost to uninsured or underinsured patients below certain income thresholds. Applications require proof of income and a valid prescription. Processing time is typically 2 to 4 weeks. Louisiana residents can apply directly through the Lilly Cares website or ask a HealthRX care coordinator to assist with the paperwork.

Is Compounded Dulaglutide Legal in Louisiana?

Compounded dulaglutide is legal in Louisiana when prepared by a licensed 503A compounding pharmacy operating under state pharmacy board oversight. Louisiana state law allows 503A pharmacies to compound patient-specific preparations of drugs that are not commercially available in a needed dose or formulation, provided a valid prescription exists. [5]

The distinction between 503A and 503B matters. A 503A pharmacy compounds for individual patients based on a specific prescription. A 503B outsourcing facility can compound in bulk without patient-specific prescriptions but must register with the FDA. Louisiana has both types operating within the state.

Dulaglutide is not on the FDA's list of drugs that are categorically prohibited from compounding (the "Demonstrably Difficult to Compound" or "Category 2" draft guidance lists do not include dulaglutide as of early 2026). This means a 503A pharmacy in Louisiana may legally prepare it for an individual patient with a valid prescription from a licensed prescriber. [6]

The cost difference compared with brand-name Trulicity is substantial. Compounded dulaglutide from a 503A pharmacy may be available for a fraction of the $931 brand-name price, depending on the pharmacy's ingredient sourcing and compounding fees. Some programs provide it at minimal cost to the patient when bundled with a telehealth subscription.

Patients considering compounded dulaglutide in Louisiana should confirm three things before filling a prescription: (1) the pharmacy holds an active Louisiana Board of Pharmacy 503A license, (2) the peptide raw material (dulaglutide API) is sourced from an FDA-registered facility, and (3) the prescribing clinician has performed a full clinical intake, not merely a checkbox form. These three verification steps reduce the risk of receiving a product of uncertain purity or potency.

Quality concerns are real. A 2024 FDA sampling survey found that a portion of compounded GLP-1 products from unregistered facilities did not meet labeled concentration standards. Licensed 503A pharmacies with certificates of analysis from accredited third-party labs offer a materially different safety profile than gray-market sources. Always request a certificate of analysis before your first fill.

Can I Get a Trulicity Prescription via Telehealth in Louisiana?

Yes. Louisiana permits telehealth prescribing of Trulicity for type 2 diabetes management. The state's telehealth laws, updated after the COVID-19 public health emergency, allow licensed Louisiana prescribers to conduct an audio-visual clinical evaluation and issue Schedule IV and non-controlled prescriptions, including dulaglutide, without a prior in-person visit. [7]

The Louisiana State Board of Medical Examiners requires that a prescriber hold an active Louisiana medical license or a valid multi-state compact license to prescribe to Louisiana residents. Out-of-state telehealth platforms that connect patients with clinicians licensed only in other states cannot legally prescribe to Louisiana patients. Before signing up for any telehealth GLP-1 service, verify that the assigned clinician holds Louisiana licensure.

A complete telehealth intake for Trulicity should include a review of your most recent A1C, fasting glucose, eGFR (dulaglutide requires dose consideration in moderate renal impairment), blood pressure, and a detailed history of pancreatitis, medullary thyroid carcinoma, or multiple endocrine neoplasia type 2 (MEN2), which are contraindications listed in the Trulicity prescribing information. [8]

HealthRX connects Louisiana patients with board-certified endocrinologists and internal medicine physicians holding active Louisiana licenses. Appointments are typically available within 48 to 72 hours. Prescriptions, when clinically appropriate, route directly to the patient's preferred pharmacy.

Trulicity Dosing, Efficacy, and Why Cost Matters Clinically

Trulicity is dosed at 0.75 mg once weekly for the first 4 weeks, then titrated to 1.5 mg once weekly as maintenance. If further glycemic control is needed, doses of 3 mg and 4.5 mg are available. All doses are delivered via a single-use autoinjector pen with a 29-gauge, 0.5 mm needle. Patients do not need to dial a dose or manually prepare the injection.

Efficacy data from the AWARD clinical program are clear. In AWARD-1 (N=976), dulaglutide 1.5 mg reduced A1C by a mean of 1.51 percentage points versus 0.05 percentage points for placebo at 26 weeks. [9] Weight loss averaged 1.3 to 3.0 kg across the AWARD studies depending on baseline characteristics and concomitant therapy.

The REWIND cardiovascular outcomes trial (N=9,901) enrolled patients with type 2 diabetes and either established cardiovascular disease or multiple CV risk factors. Dulaglutide 1.5 mg once weekly reduced the composite MACE endpoint (nonfatal MI, nonfatal stroke, or CV death) by a hazard ratio of 0.88 (95% CI 0.79 to 0.99, P<0.026) versus placebo over a median follow-up of 5.4 years. [4] REWIND is notable because roughly 69% of its enrollees had CV risk factors rather than established disease, broadening the population in which the drug shows benefit.

The Lancet's published report on REWIND noted that "dulaglutide could be considered for glycaemic management in middle-aged and older people with type 2 diabetes who have either established cardiovascular disease or cardiovascular risk factors." [4] That recommendation carries direct weight for Louisiana prescribers writing prior authorization letters.

Cost affects outcomes. A retrospective adherence study published in Diabetes Care found that GLP-1 receptor agonist discontinuation rates exceeded 50% within 12 months in commercially insured patients paying copays above $100 per month, compared with 28% discontinuation in patients with copays below $30. [10] In Louisiana, where a substantial portion of the adult population is uninsured or on Medicaid, the $931 cash price creates a near-complete barrier for many patients who would otherwise be appropriate candidates based on their A1C and cardiovascular risk profile.

What Is the Cheapest Way to Get Trulicity in Louisiana?

The lowest realistic out-of-pocket path depends on your insurance status.

For commercially insured patients: Use the Eli Lilly savings card. Copay can drop to $25/month. This is the single most impactful step for anyone with private insurance.

For uninsured patients above Medicaid income limits: Apply to the Lilly Cares Foundation patient assistance program. Approval typically takes 2 to 4 weeks and provides the brand-name drug at no cost.

For uninsured patients below Medicaid income limits: Louisiana Medicaid does not cover dulaglutide, so Medicaid enrollment does not solve the problem directly. Lilly Cares remains the best option. A licensed 503A-compounded dulaglutide from a Louisiana or Louisiana-shipping pharmacy is a second option with close clinical monitoring.

For Medicare patients: The Medicare Part D coverage gap ("donut hole") has been restructured by the Inflation Reduction Act, capping out-of-pocket Part D costs at $2,000 annually starting in 2025. For Medicare patients whose total Part D spending exceeds that threshold, Trulicity fills become $0 for the rest of the calendar year. Patients who hit the cap early in the year may find the annual cost manageable. [11]

GoodRx coupons for Trulicity in Louisiana typically show prices in the $830 to $900 range at major chains, which is lower than the $931 list price but not dramatically so. GoodRx cannot be combined with insurance. It functions as an alternative payment method, not a supplement.

Monitoring Parameters and Safety Considerations for Louisiana Patients

Dulaglutide carries a boxed warning for thyroid C-cell tumors based on rodent studies. The clinical relevance in humans remains uncertain, but patients with a personal or family history of medullary thyroid carcinoma or MEN2 should not use Trulicity. [8]

Common side effects include nausea (occurring in 12 to 29% of patients across the AWARD program), diarrhea, vomiting, and abdominal pain. These are most pronounced during dose titration and typically diminish after 4 to 8 weeks. Injecting immediately after eating can reduce nausea intensity.

Renal monitoring is warranted. While dulaglutide does not require dose adjustment for mild-to-moderate chronic kidney disease, cases of acute kidney injury have been reported secondary to dehydration from GI side effects. Louisiana patients managing diabetes in a hot, humid climate should be counseled explicitly on fluid intake during summer months.

Patients with an eGFR <15 mL/min/1.73m² should use dulaglutide only with caution and close nephrology involvement. The drug has not been studied adequately in end-stage renal disease requiring dialysis.

Drug interactions are limited compared with other diabetes classes. Dulaglutide slows gastric emptying, which may reduce the absorption rate (though not necessarily the total bioavailability) of co-administered oral medications including levothyroxine and oral contraceptives. These interactions are generally manageable with timing adjustments rather than dose changes.